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Introduction
The transplantation of human cells shows promising 
opportunities for the treatment of a number of diseases, 
some of which are as yet incurable. To ensure the provi-
sion of safe and reliable cells and tissues for clinical use, 
national and international guidelines and regulations 
have been issued to regulate the procurement, process-
ing, testing, preservation, storage and distribution of all 
cells aimed for application in the human body [1-7]. The 
implementation of a quality assurance (QA) programme 
including the principles of Good Manufacturing Practice 
(GMP) and a quality control system is a major require-
ment, as shown previously [8-10]. Like drugs, cells and 
tissues for therapeutic use are regulated in Europe by the 
Rules Governing Medicinal Products [2]. GMP regula-
tions apply to all phases of cell collection, processing 
and storage, as well as documentation, training of per-
sonnel, and the laboratory facility [9, 11-13]. In Italy, 
all laboratories involved in the production of cells and 
tissues for therapeutic use must undergo inspection and 
authorisation in conformity with a Ministry of Health 
Decree [14]. Because of the specificity of cells and tis-
sues, regulations have changed in recent years, and are 
still evolving: Annex 1 of European Commission (EC) 
Guide to GMP [15-17] in particular, sets the require-
ments for the level of airborne particulate classification.
The processing of cell cultures for use in human therapy 
protocols requires a physical environment in which air 
quality is controlled, in order to minimise the risk of con-
tamination. The cell factory should be constructed and 
operated as to minimise the introduction and retention of 
particles and micro-organisms [18-20], and a formal pro-
gramme of environmental monitoring should be set up 
within the QA programme implementation, in accordance 
with the GMP principles [21-23]. The main objective is 
to maintain a controlled environment that minimise the 
risk of infecting patients. The environmental monitoring 
programme should include a series of physical controls 
(concentration of particles in the air, flow of air, integrity 
of HEPA filters, differential pressure, temperature, rela-
tive humidity) and microbiological controls (microbial 
status of air quality by particle counting and microbio-
logical culture, microbial surface contamination). Other 
aspects should also be determined: frequency, location 
and duration of sampling, establishment of “alert” and 
“action” levels, monitoring of the personnel. 
There are two methods of measuring the microbial con-
tamination of air: active air sampling, in which micro-
bial air contamination can be measured by counting the 
number of colony-forming units (cfu) per cubic me-
tre, and passive air sampling by counting cfu on settle 
plates [24, 25]. The advantages and disadvantages of 
each method have been described previously [26, 27]. 
Original article
Environmental monitoring programme  
in the cell therapy facility of a research centre: 
preliminary investigation
G. OTTRIA, M. DALLERA, O. ARESU*, M.A. MANNIELLO*, B. PARODI*, A.M. SPAGNOLO, M.L. CRISTINA
Department of Health Sciences, University of Genoa, Italy; * National Institute for Research on Cancer (IST), Genoa, Italy
Key words
Cell	therapy	•	Environmental	monitoring	•	Good	Manufacturing	Practice	(GMP)
Summary
Introduction. Recent discoveries in cell therapy research present 
new opportunities for cellular products to be used to treat severe, 
and as yet incurable, diseases. It is therefore essential to imple-
ment a quality control programme in order to ensure that safe 
cells and tissues are provided.
Methods. In a preliminary phase of the setting up of a the cell fac-
tory, monitoring was carried out monthly over a 6-month period 
in one out of three cell therapy laboratories and filter rooms in 
order to evaluate the microbial contamination of air and surfaces 
and the presence of airborne particulates. 
Results. The mean total bacterial and fungal loads measured in 
the air in the centre of the filter room were 20.7 ± 28.9  colony-
forming units (cfu)/m3 and 9.2 ± 15.4 cfu/m3, respectively, and 
5.2 ± 4.1 cfu/m3 and 6.8 ± 13.4 cfu/m3, respectively, in the labo-
ratory. The mean fungal load values recorded on the surfaces 
sampled in the laboratory were in 6 out of 18 cases higher than 
the reference values (5 cfu/plate). As to the results of particulate 
monitoring, with regard to the 0.5 µm particles, about 83% of 
the samples revealed values below the limit of 350.000 particles 
per cubic metre. 
Conclusions. In this set-up phase, monitoring was able to pick 
out structural and organisational flaws acceptable in a laboratory 
compliant with Good Manufacturing Practices class C (Annex 1), 
but not in a class B facility. Thanks to this preliminary monitoring 
phase, and by correcting these flaws, the clean room facility could 
achieve compliance to class B.
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The microbial monitoring of surfaces can provide a 
valuable estimate of the level of contamination on sur-
faces such as walls, work surfaces, floors and equip-
ment. Various methods utilise contact plates, swabbing 
and bioluminescence techniques [26, 28, 29]. The most 
common methods use contact plates and follow the rec-
ommendations of the European and the US Pharmaco-
poeia [30, 31]; micro-organisms being visualised as 
colonies after incubation and the results being expressed 
as the number of cfu per plate. 
This paper presents the results of the environmental 
monitoring programme carried out during the set-up 
phase of the three-laboratory cell therapy facility of the 
National Institute of cancer Research in Genoa. The 
laboratories were originally built to be compliant with 
class C, and had to be subsequently upgraded to class 
B. Each laboratory has its own dedicated equipment, so 
that individual patients cell manipulations and/or cul-
tures can be physically isolated. Cross-contamination 
is minimised by standard operating procedures and an 
electronic door opening system. All operations requiring 
open manipulation of patient tissues are carried out in 
class A biological safety cabinets. Facility access is re-
stricted to authorised, trained personnel. Fully redundant 
air-handling systems are used, and the laboratories are 
routinely monitored for viable and nonviable air particu-
late counts and surface microbial contamination.
Methods
Monitoring was carried out monthly over a 6-month pe-
riod in order to evaluate the microbial contamination of 
the air and surfaces and the presence of airborne particu-
lates in one out of three cell therapy laboratories and the 
corresponding filter rooms. The microbiological and par-
ticulate samplings were carried out, in at rest conditions, 
by trained personnel wearing sterile protective clothing 
for clean room; the surface of all the instruments used 
was accurately disinfected with 70% isopropyl alcohol.
Microbiological monitoring
The total microbial and fungal count was carried out on 
representative surfaces (work bench, upper horizontal 
surface of the refrigerator and surface of the cable con-
duit in the laboratory; surface of the washbasin in the 
filter room), in the air in the centre of the room and in the 
air emerging from the outlet ports of the air-conditioning 
system. RODAC plates (diameter: 55 mm, surface area: 
24 cm2) containing respectively γ-irradiated TSA medi-
um for total microbial count and Sabouraud medium for 
fungal count were utilized.
Active sampling of the air in the centre of the room and 
of the air emerging from the air-conditioning outlets 
was carried out by means of a SAS super 100 aspirator 
(International Pbi S.p.A.). The volumes of air aspirated 
were 500 litres in the centre of the room and 1000 litres 
from the outlets (2 outlet ports in the laboratory and 1 in 
the filter room). In order to prevent contamination, after 
sampling every plate was sealed and carried to the qual-
ity control laboratory in a biocarrier. 
For the total bacterial count, the plates were incubated at 
37°C for 48 hours; for the total fungal count, the plates 
were incubated at 25°C for at least five days.
The results were expressed as cfu/plate for the surface 
bacterial and fungal counts and as cfu/m3 for the airborne 
bacterial and fungal counts. In the statistical analysis, 
the value “ < 1” was considered equal to “0”. 
Particulate monitoring
Particulate monitoring was carried out in conformity 
with the UNI EN ISO 14644-1 [19] and 14644-2 [32] 
norm. In accordance with this norm, 2 sampling points 
in the filter room (5,40 m2) and 4 sampling points in 
the laboratory (12,69 m2) were identified, uniformly 
distributed through the room area. The apparatus used 
was the particle counter MET ONE Mod. 227A Pacific 
Scientific Instruments (sampling load: 2.83 L/minute). 
Sampling was performed at working bench level, and 
the probe was pointed vertically upwards.
The results were expressed as the number of particles 
per cubic metre.
Results
Air microbiological monitoring 
Results of total bacterial and fungal load, measured in 
the air in the center of the room and in the air emerging 
from the air-conditioning outlet ports in each room, are 
described in Tables I and II respectively.
The mean total bacterial and fungal loads measured in 
the air in the centre of the filter room were 20.7 ± 28.9 
cfu/m3 and 9.2 ± 15.4 cfu/m3, respectively, and 5.2 ± 4.1 
Tab. I. total bacterial and fungal load measured in the air in the center of the room (cfu/m3); mean values and standard deviations (Sd). recom-
mended limits: 10 cfu/m3, according to eU-gmp annex 1, 2003.
Bacterial and fungal load (cfu/m3)
JUL AUG SEP OCT NOV DEC Mean ± SD
Filter room
< 1
< 1
2
2
34
7
8
< 1
74
40
6
6
20.7 ± 28.9
9.2 ± 15.4
Bacteria
Fungi
laboratory
8
< 1
1
2
4
< 1
10
4
8
34
< 1
1
5.2 ± 4.1
6.8 ± 13.4
Bacteria
Fungi
mOnitOring in the cell therapy Facility
135
cfu/m3 and 6.8 ± 13.4 cfu/m3, respectively, in the labora-
tory, as reported in Table I.
Microbiological analysis of the air revealed mean values 
above the reference values (10 cfu/m3) only with regard 
to the bacterial load in the filter room. The reference 
standards were respected in 83% of observations with 
regard to both the bacterial and fungal loads. The high-
est level of contamination was recorded in the month of 
November (Tab. I).
As shown in Table II, all the data concerning the air sup-
plied by the outlet ports of the air-conditioning system 
conformed to the standards, with the exception of the 
November analysis. In approximately 47% of the obser-
vations carried out, the air proved to be microbiologi-
cally pure; in about 47% of samples revealed no bacte-
rial contamination, and in approximately 87% of cases 
no fungal load was recorded.
Surfaces microbiological monitoring
Results of total bacterial and fungal counts on surfaces 
in each sampling are reported in Table III. The results 
obtained, expressed as cfu/plate, revealed that the mean 
fungal load values recorded on the surfaces sampled in 
the laboratory were in 6 out of 18 cases higher than the 
reference values (5 cfu/plate); this was particularly true 
for the surface of the cable conduit. In all other cases, the 
mean values recorded were below the reference values; 
all the measurements of surface bacterial loads, and 71% 
of those of surface fungal loads, proved to be lower than 
the standards considered.
Particulate monitoring
The results of the particle counts at the individual sam-
pling points during each sampling in the laboratory and 
in the filter room are reported in Tables IV and V re-
spectively.
With regard to the small-diameter (0.5 µm) particles, 
about 83% of the samples taken, both in the laboratory 
and in the filter room, revealed values below the refer-
ence limit of 350.000 particles per cubic metre. On con-
sidering the large-diameter (5 µm) particles and the cor-
responding limit of 2.000 particles per cubic metre, the 
percentages were 100% and about 92% in the laboratory 
and filter room, respectively.
Discussion and conclusion 
The present paper describes the initial phase of a pro-
gramme of environmental monitoring, drawn up in ac-
cordance with the EC Guide to Good Manufacturing 
Practice, Annex 1 [15] prior to its 2008 revision [16]. 
The initial objective was to meet the requirements laid 
down for class C environments, with a view subsequent-
ly to fulfilling those prescribed for the higher class B.
The results obtained at the end of this initial phase yield-
ed useful information on which to assess the current 
situation as to both microbial contamination of air and 
surfaces and particulate status of the air.
The norm does not indicate limits on microbial con-
tamination in at-rest conditions; with regard to par-
Tab. II. total bacterial load (Bl) (cfu/m3), fungal load (Fl) (cfu/m3) measured in the air emerging from the air-conditioning outlet ports; mean 
values and standard deviations (Sd). recommended limits: 10 cfu/m3, according to eU-gmp annex 1, 2003.
Laboratory Filter Room
OUTLET 1 OUTLET 2 OUTLET 3
Month BL (cfu/m3) FL (cfu/m3) BL (cfu/m3) FL (cfu/m3) BL (cfu/m3) FL (cfu/m3)
Jul
Aug
Sep 
Oct
Nov
Dec
< 1
1
< 1
< 1
80
< 1
< 1
< 1
< 1
< 1
20
< 1
1
1
1
< 1
57
3
< 1
< 1
< 1
< 1
22
1
1
< 1
< 1
1
29
1
 < 1
 < 1
 < 1
 < 1
43
2
Mean ± SD 13.5 ± 32.6 3.3 ± 8.2 10.5 ± 22.8 3.8 ± 8.9 5.3 ± 11.6 7.5 ± 17.4
Tab. III. total bacterial load (Bl), fungal load (Fl) measured on some surfaces (cfu/plate); mean values and standard deviations (Sd). recom-
mended limits: 5 cfu/plate, according to eU-gmp annex 1, 2003.
Laboratory (cfu/plate) Jul Aug Sep Oct Nov Dec Mean ± SD
Upper surface of work bench
Bl
Fl
< 1
< 1
< 1
3
< 1
< 1
1
27
1
13
1
2
0.5 ± 0.5
7.5 ± 10.7
Upper surface of cable conduit
Bl
Fl
< 1
< 1
< 1
4
< 1
159
3
46
< 1
< 1
< 1
2
0.5 ± 1.2
35.2 ± 63.2
Upper surface of refrigerator
Bl
Fl
< 1
< 1
< 1
16
< 1
1
2
52
< 1
< 1
< 1
1
0.3 ± 0.8
11.7 ± 20.7
Filter Room (cfu/plate) Jul Aug Sep Oct Nov Dec Mean ± SD
Washbasin
Bl
Fl
< 1
< 1
< 1
6
< 1
< 1
< 1
< 1
< 1
1
< 1
< 1
0 ± 0
1.2 ± 2.4
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ticulate contamination, however, it indicates limits for 
each class during operating conditions, equal to those 
applicable to the class below it in at-rest conditions. It 
was therefore decided that, as reference values for mi-
crobial contamination in at-rest conditions, the present 
study should utilise those prescribed for class B in op-
erating conditions (10 cfu/m3 in air; 5 cfu/plate on sur-
faces).
The results of microbiological analysis of the air re-
vealed mean values above the reference values only 
with regard to the bacterial load in the filter room and 
the highest level of contamination was recorded in No-
vember. This was confirmed by the data concerning the 
air supplied by the outlet ports of the air-conditioning 
system: the only data non complying with the standards 
were found in the November analysis (Tab. II). The high 
Tab. IV. laboratory – number of particles (0.5-5 µm) per cubic meter measured at each point in each sampling; mean values and standard 
deviations (Sd). maximum permitted number of particles/m3: 350 000 (0.5 µm) and 2000 (5 µm), according to eU-gmp annex 1, 2003.
Laboratory 
Month Particle size (µm) Point 1 Point 2 Point 3 Point 4 Mean ± SD
Jul
0.5 16 254 27 208 19 435 33 216 24 028 ± 7661
5 0 0 0 0 0 ± 0
Aug
0.5 114 134 86 926 83 746 89 399 93 551 ± 13 916
5 0 353 0 0 88 ± 177
Sep
0.5 94 700 98 233 106 714 140 283 109 983 ± 20 820
5 353 0 353 353 265 ± 177
Oct
0.5 251 237 232 862 307 420 290 106 270 406 ± 34 327
5 0 0 353 0 88 ± 177
Nov
0.5 263 251 258 304 296 820 292 933 277 827 ± 19 854
5 353 0 707 353 353 ± 289
Dec
0.5 962 898 867 138 590 459 693 286 778 445 ± 167 810
5 0 0 0 0 0 ± 0
Mean
0.5 283 746 261 779 234 099 256 537
5 118 59 236 118
SD
0.5 346 059 309 726 210 341 238 547
5 182 144 289 182
Tab. V. Filter room– number of particles (0.5 – 5 µm) per cubic meter measured at each point in each sampling; mean values and standard 
deviations (Sd). maximum permitted number of particles/m3: 350 000 (0.5 µm) and 2000 (5 µm), according to eU-gmp annex 1, 2003.
Filter room
Month Particle size (µm) Point 1 Point 2 Mean ± SD
Jul
0.5 18 375 28 622 23 499 ± 7246
5 0 1767 884 ± 1249
Aug
0.5 74 205 72 438 73 322 ± 1249
5 1767 353 1060 ± 1000
Sep
0.5 73 145 75 618 74 382 ± 1749
5 0 353 177 ± 250
Oct
0.5 311 661 319 081 315 371 ± 5247
5 0 0 0 ± 0
Nov
0.5 311 661 286 926 299 294 ± 17 490
5 1767 3180 2474 ± 999
Dec
0.5 615 901 511 661 563 781 ± 73 709
5 0 0 0 ± 0
Mean
0.5 234 158 215 724
5 589 942
SD
0.5 226 192 188 944
5 912 1277
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values, observed simultaneously in both the rooms mon-
itored, pointed to a malfunction of the air-conditioning 
system in the period between the October and November 
sampling. Indeed, the investigation revealed that the sys-
tem had suffered a short breakdown during that period. 
Prompt intervention to repair the fault soon brought the 
microbiological parameters back in line with the values 
registered previously. This demonstrates the importance 
not only of having an air-conditioning system that can 
quickly recover its functional capacity, but also of estab-
lishing adequate routine maintenance procedures aimed 
at preventing emergencies and of creating an organisa-
tion that can ensure a rapid response to unexpected, and 
sometimes critical, problems. 
In order to evaluate the bacterial and fungal contamina-
tion of surfaces, some representative surfaces potential-
ly exposed to microbial contamination were identified. 
The results obtained, expressed as cfu/plate, revealed 
that the mean fungal load values in some cases were 
higher than the reference values; this was particularly 
true for the surface of the cable conduit in the labora-
tory. On the basis of this evidence it was decided that: 
a) the QA Responsible should reassess cleaning pro-
cedures; b) potential sites where microbes might settle 
and proliferate should be removed (i.e. electrical cables 
should be embedded in walls rather than running in ex-
ternal conduits).
The status of the air was assessed by considering par-
ticle diameters of 0.5 µm and 5 µm, as indicated in 
EU-GMP Annex 1. The mean values recorded at each 
sampling point did not allow us to pick out any consist-
ently critical positions of contamination in either of the 
environments with regard to either of the particle sizes 
considered. The gradual increase in the number of 0.5 
µm particles observed in both environments over the 
samplings may be regarded as indicating a progressive 
decline in the filtration efficiency of the air-conditioning 
system and in its ability to screen out the finer particles. 
This may also be interpreted as a useful early warning of 
a brief temporary breakdown of the ventilation system. 
These considerations underline the key role of particu-
late monitoring as a means of assessing the efficacy of 
air-conditioning systems and as an adjunct to the normal 
control and maintenance of system components, such as 
absolute filters. The above-limit values of 0.5 µm par-
ticles were all recorded during the December sampling, 
and the only above-limit value of 5 µm particles was 
observed in November. The explanation for this may be 
that the time interval between the repair work carried 
out on the air-conditioning system and the subsequent 
sampling was too short. While it may well have been 
sufficient to allow the 5 µm particles to be brought back 
within the proper limit, it does not seem to have been 
long enough to enable the number of finer (0.5 µm) 
more persistent airborne particles to be reduced suffi-
ciently.
In conclusion, in this set-up phase, microbiological and 
particulate monitoring provided information able to con-
tribute to the efforts to comply, from both a structural 
and procedural point of view, to GMP regulations. Once 
the critical points have been dealt with, validation of the 
environments, equipment and processes was carried out, 
at rest and in operation, including biological safety cabi-
nets. The continuous monitoring yields an abundance 
of significant microbiological data that are used for the 
trend analysis program, to make sure that the operating 
conditions are good enough to allow the facility to be 
used for cell therapy activities.
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